Targeting synuclein-gamma to counteract drug resistance in cancer.
BACKGROUND
Expression of synuclein-gamma (SNCG) protein is elevated in the advanced stages of many types of cancers, including ovarian, lung, liver, esophagus, colon, prostate and, in particular, breast. In breast carcinoma, SNCG is causatively linked to stimulated proliferation, metastasis and drug resistance.


OBJECTIVE
To establish SNCG as a potential therapeutic target and to discuss clinical use of SNCG inhibiting peptide.


METHODS
This review focuses on the plausible mechanisms of SNCG activity, SNCG mediated drug resistance and its inhibition.


CONCLUSIONS
Evidence based research shows that the aberrant expression of SNCG has a strong correlation with breast cancer progression and poor clinical outcome. A peptide based inhibitor counters activity of SNCG, which may be developed as an adjuvant therapy.
Singh
Vinay K
VK
CIHR Post-doctoral Fellow in Transdisciplinary Cancer Research, Queen's University, Department of Biochemistry, Kingston, Ontario, K7L 3N6, Canada.
Jia
Zongchao
Z
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D016503:Drug Delivery Systems / Q000379:methods*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D010455:Peptides / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D051845:gamma-Synuclein / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000378:metabolism*
D000970:Antineoplastic Agents; D010455:Peptides; D051845:gamma-Synuclein